Q2 2025 · 13F-HR
Vivo Capital, LLCholdings as filed
Filed 2025-08-14 · accession 0001213900-25-075901
$977.1M
Reported value
42
Positions
2025-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 834203309 | SLNO | Soleno Therapeutics Inc | $331.6M | 33.9% | 3,958,294 | Common | SOLE |
| 925050106 | VRNA | Verona Pharma PLC | $131.8M | 13.5% | 1,393,432 | Common | SOLE |
| 171757206 | CDTX | Cidara Therapeutics, Inc. | $63.9M | 6.54% | 1,311,425 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $38.4M | 3.93% | 27,225,292 | Common | SOLE |
| P8696W104 | SVA | Sinovac Biotech Ltd. | $38.2M | 3.91% | 5,903,000 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $31.7M | 3.25% | 3,126,604 | Common | SOLE |
| 880881107 | 430 | Terns Pharmaceuticals Inc | $25.7M | 2.63% | 6,895,746 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $24.5M | 2.51% | 4,487,903 | Common | SOLE |
| G29687103 | AVDL | Avadel Pharmaceuticals PLC | $23.8M | 2.43% | 2,684,109 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $23.2M | 2.37% | 434,689 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics Inc | $15.7M | 1.61% | 6,043,466 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $13.7M | 1.41% | 982,576 | Common | SOLE |
| 23284F105 | CTMX | Cytomx Therapeutics Inc | $13.1M | 1.34% | 5,769,230 | Common | SOLE |
| 00461U105 | ACRS | Aclaris Therapeutics, Inc. | $12.6M | 1.29% | 8,888,888 | Common | SOLE |
| 98937L105 | ZBIO | Zenas Biopharma Inc | $11.5M | 1.17% | 1,183,260 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $10.6M | 1.09% | 1,114,960 | Common | SOLE |
| 00289Y206 | ABEO | Abeona Therapeutics, Inc. | $10.5M | 1.07% | 1,842,751 | Common | SOLE |
| 23306J309 | DBVT | DBV Technologies SA | $9.7M | 0.99% | 1,054,506 | Common | SOLE |
| 89157D105 | TRML | Tourmaline Bio Inc. | $9.5M | 0.97% | 591,882 | Common | SOLE |
| 76200L309 | RZLT | Rezolute Inc | $9.4M | 0.96% | 2,112,432 | Common | SOLE |
| 20451W101 | CMPS | Compass Pathway PLC | $9.4M | 0.96% | 3,362,385 | Common | SOLE |
| 221015100 | CRVS | Corvus Pharmaceuticals Holdings | $8.9M | 0.91% | 2,234,566 | Common | SOLE |
| 449778109 | IOBTQ | IO Biotech Inc | $8.6M | 0.88% | 6,173,439 | Common | SOLE |
| 29479A108 | ERAS | Erasca Inc | $8.6M | 0.88% | 6,756,756 | Common | SOLE |
| 04635X102 | CATBUSD | Astria Therapeutics Inc | $8.3M | 0.85% | 1,552,685 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc | $8.2M | 0.83% | 610,500 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $8.1M | 0.82% | 1,122,471 | Common | SOLE |
| 24661P807 | DCTH | Delcath Systems, Inc. | $7.7M | 0.79% | 569,526 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines | $7.0M | 0.72% | 167,600 | Common | SOLE |
| 10919W405 | DRUG | Bright Minds Biosciences Inc | $6.6M | 0.67% | 251,572 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $6.4M | 0.66% | 1,505,862 | Common | SOLE |
| 82686Q101 | SLN | Silence Therapeutics PLC | $6.4M | 0.66% | 1,105,454 | Common | SOLE |
| 92337C203 | VSTM | Verastem Inc | $6.4M | 0.65% | 1,538,461 | Common | SOLE |
| 45783C200 | TIL | Instil Bio Inc | $6.1M | 0.62% | 292,743 | Common | SOLE |
| 90466Y202 | UNCY | Unicycive Therapeutics | $5.4M | 0.56% | 1,137,015 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics Inc | $4.6M | 0.47% | 1,650,440 | Common | SOLE |
| 282559103 | ETNBGBP | 89Bio Inc | $3.7M | 0.38% | 376,804 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics Inc | $3.1M | 0.31% | 600,000 | Common | SOLE |
| 86889P208 | SRZN | Surrozen Inc | $2.3M | 0.24% | 260,000 | Common | SOLE |
| 88032L605 | TENX | Tenax Therapeutics Inc | $1.2M | 0.12% | 208,333 | Common | SOLE |
| 097702203 | BOLT | Bolt Therapeutics Inc | $985,958 | 0.10% | 176,064 | Common | SOLE |
| 74019P207 | DTIL | Precision Biosciences Inc | $19,636 | 0.00% | 4,675 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.